CD276 Targeted Therapies Clinical Trials & Market Opportunity Insight Report 2026 - First CD276 Therapy Approval Anticipated by 2028 [Yahoo! Finance]
Fate Therapeutics, Inc. (FATE)
Last fate therapeutics, inc. earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fatetherapeutics.com/investor-relations
Company Research
Source: Yahoo! Finance
Key areas include antibody-drug conjugates, CAR T-cell treatments, and bispecific antibodies targeting difficult cancers. Strategic partnerships and platform innovations are driving global expansion and therapeutic potential. Dublin, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The "Global CD276 Targeted Therapies Clinical Trials & Market Opportunity Insight 2026" report has been added to ResearchAndMarkets.com's offering. CD276, or B7-H3, has become one of the most exciting next-generation targets in immuno-oncology. Its uniform overexpression across the broadest range of solid tumors, and negligible expression in normal tissue, renders it a highly desirable target for precision medicines. With the industry moving from first-generation checkpoint inhibitors towards more tumor-specific strategies, CD276 is picking up speed in drug development pipelines worldwide. This report offers a targeted view of the emerging CD276 targeted therapeutics market. It identifies pivotal clinical programs,
Show less
Read more
Impact Snapshot
Event Time:
FATE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FATE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FATE alerts
High impacting Fate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FATE
News
- Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business UpdatesGlobeNewswire
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Fate Therapeutics (NASDAQ:FATE) had its "neutral" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
FATE
Earnings
- 11/13/25 - Beat
FATE
Sec Filings
- 11/13/25 - Form 10-Q
- 11/13/25 - Form 8-K
- 10/27/25 - Form 8-K
- FATE's page on the SEC website